Live Breaking News & Updates on Corina Dutcus

Stay updated with breaking news from Corina dutcus. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

KEYTRUDA (pembrolizumab) Plus LENVIMA (lenvatinib) Demonstrates Long-Term, Durable Survival Benefit Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma

25.05.2023 - Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai today announced data from the final pre-specified overall survival (OS) analysis of the pivotal Phase 3 CLEAR (Study 307)/KEYNOTE-581 trial investigating KEYTRUDA, . ....

United States , New Zealand , Gregory Lubiniecki , Corina Dutcus , Thomas Hutson , Global Clinical Development , International Metastatic , Eisai Co Ltd , Urologic Cancer Research , Database Consortium , Merck Research Laboratories , Eisai Europe Ltd , Treatment Center , Merck Co Inc , Urologic Oncology Program , Statement Of Merck Co Inc , Clinical Development , United Nations Sustainable Development Goals Sdgs , Eisai Inc , Texas Oncology At Baylor Sammons Cancer Center , Exchange Commission , Memorial Sloan Kettering Cancer Center , Oncology At Eisai Inc , Merck Co Stock , Texas Oncology , Baylor Sammons Cancer ,

Keytruda/Lenvima Trials Stop Due to Lack of Benefit

Two clinical trials investigating Keytruda plus Lenvima will be discontinued after the drug duo was not superior to other regimens for melanoma and colorectal cancer subsets. ....

Keytruda Lenvima , Gregory Lubiniecki , Corina Dutcus , Merck Research Laboratories , Global Clinical Development , Eisai Inc , Vice President , Skin Cancer , Colorectal Cancer ,

Eisai : and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 Trials of LENVIMA® (lenvatinib) Plus KEYTRUDA® (pembrolizumab) in Certain Patients With Advanced Melanoma (LEAP-003) and Metastatic Colorectal Cancer (LEAP-017)

Eisai Co., Ltd.

Merck & Co., Inc., Rahway, NJ, USA

. | April 7, 2023 ....

United States , Peter Dannenbaum , Haruo Naito , Damini Chokshi , Corina Dutcus , Gregory Lubiniecki , John Infanti , Julie Cunningham , Oncology At Eisai Inc , Data Monitoring Committee , Merck Co Inc , United States Research Laboratories , Clinical Development , Eisai Co Ltd , Global Clinical Development , United States Provide Update , Certain Patients With Advanced Melanoma , Metastatic Colorectal Cancer , Vice President , United States Research , Senior Vice President , Response Evaluation Criteria , Solid Tumors , Eisai Co , Td Stock Exchange , Press Release ,

Merck and Eisai Provide Update on Phase 3 Trials of KEYTRUDA (pembrolizumab) Plus LENVIMA (lenvatinib) In Certain Patients With Advanced Melanoma (LEAP-003) and Metastatic Colorectal Cancer (LEAP-017)

07.04.2023 - Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai today provided updates on two Phase 3 trials, LEAP-003 and LEAP-017 investigating KEYTRUDA, Merck’s anti-PD-1 therapy, plus LENVIMA, the orally available multiple . ....

United States , New Zealand , Gregory Lubiniecki , Corina Dutcus , Exchange Commission , Merck Co Stock , Data Monitoring Committee , Merck Co Inc , Eisai Co Ltd , Merck Research Laboratories , Oncology At Eisai Inc , Eisai Europe Ltd , Statement Of Merck Co Inc , Clinical Development , United Nations Sustainable Development Goals Sdgs , Global Clinical Development , Eisai Inc , Vice President , Merck Research , Senior Vice President , Response Evaluation Criteria , Solid Tumors , Mismatch Repair Deficient Colorectal , Selected Important Safety , Important Safety Information , Fatal Immune Mediated Adverse ,

Merck and Eisai Provide Update on Phase 3 Trials of KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) In Certain Patients With Advanced Melanoma (LEAP-003) and Metastatic Colorectal Cancer (LEAP-017)

Merck , known as MSD outside of the United States and Canada, and Eisai today provided updates on two Phase 3 trials, LEAP-003 and LEAP-017 investigating KEYTRUDA, Merck’s anti-PD-1 therapy,. | April 7, 2023 ....

United States , New Zealand , Corina Dutcus , Gregory Lubiniecki , Oncology At Eisai Inc , Merck Co Inc , Data Monitoring Committee , Statement Of Merck Co Inc , Global Clinical Development , Eisai Inc , Merck Research Laboratories , Exchange Commission , Eisai Europe Ltd , Eisai Co Ltd , Clinical Development , United Nations Sustainable Development Goals Sdgs , Vice President , Merck Research , Senior Vice President , Response Evaluation Criteria , Solid Tumors , Mismatch Repair Deficient Colorectal , Selected Important Safety , Important Safety Information , Fatal Immune Mediated Adverse , Which Can Present With Diabetic ,